The recent Supreme Court ruling on the Myriad Genetics patent dispute was monumental for the IVD market. Its 17-year monopoly on BRCA testing for genetic risk for breast, ovarian cancer was brought to an end. According to Kalorama Information, this decision couldn't have come any sooner. In my opinion, they're right.
In plain terms, the Supreme Court ruled that a company can't patent genes that naturally exist. On the other hand, genes that are developed by a company in a lab comfortably fall under intellectual property protection. This is good news for the sake of innovation and progress in the Cancer Diagnostics market. Human genes can't be patented. It should be common sense, but we all know that common sense isn’t always common.